Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Kristi McIntyre · Joyce O'Shaughnessy ·
Lee Schwartzberg · Stefan Glück · Erhan Berrak ·
James X. Song · David Cox · Linda T. Vahdat

Published online: 19 June 2014
© Springer Science+Business Media New York 2014

Erratum to: Breast Cancer Res Treat DOI 10.1007/s10549-014-2923-9

Unfortunately, in the original publication of the article, a statement in the third paragraph of the discussion section has been published with an error.

The statement in the discussion currently reads: However, neutropenia did not appear to substantially influence efficacy outcomes; among subjects with or without neutropenia grade

3 or lower ($n = 28$ in each group), the ORR was 8/28 in each group and median PFS was 208 days (with) compared with 203 days (without).

The correct statement is: However, neutropenia did not appear to substantially influence efficacy outcomes; among subjects with or without neutropenia grade **3/4** ($n = 28$ in each group), the ORR was 8/28 in each group and median PFS was 208 days (with) compared with 203 days (without).

The online version of the original article can be found under doi:[10.1007/s10549-014-2923-9](https://doi.org/10.1007/s10549-014-2923-9).

K. McIntyre
Texas Oncology-Dallas Presbyterian Hospital, US Oncology,
Dallas, TX, USA

J. O'Shaughnessy
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Dallas, TX, USA

L. Schwartzberg
West Clinic, Memphis, TN, USA

S. Glück
Sylvester Comprehensive Cancer Center, University of Miami,
Miami, FL, USA

E. Berrak · J. X. Song · D. Cox
Eisai Inc., Woodcliff Lake, NJ, USA

L. T. Vahdat (✉)
Weill Cornell Medical College, 425 East 61st Street, 8th Floor,
New York, NY 10065, USA
e-mail: ltv2001@med.cornell.edu